NY-ESO-1 specific TCR-HEK293 cell line

1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
3. Comprehensive application data to support assay development and validation
4. Full tracible record, stringent quality control and validated cell passage stability
5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
6. Global commercial license assistance whenever regulatory filing is required

如有相关细胞池需求请联系我们

背景（Background）

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. This cell can specifically recognize HLA-A2/NY-ESO-1.

Limited Use&License Disclosure

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use . You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.